Medical Director, CAR-T & Cellular Therapy

Plexus Partners Ltd; Los Angeles (CA); Presencial; USD 250 000 - 450 000; Tempo integral

Vantagens oferecidas por esta oferta de emprego

Relocation support

Full benefits

Malpractice cover

CME allowance

Leadership access

Resumo da oferta

Plexus Partners Ltd in Los Angeles seeks a Medical Director specialized in CAR-T and cellular therapy. You will build and lead a dedicated unit, supervise industry-sponsored trials from Phase I to III, and partner with leadership on feasibility and sponsor development.

California licensure and board certification are required. You will ensure protocol conduct, patient safety, and FDA/ICH GCP compliance, while mentoring junior investigators as the team expands.

Qualificações

• MD/DO with CA medical license and board certification in oncology.
• Hands-on CAR-T or cellular therapy trial experience as PI/Sub-I.
• Strong knowledge of FDA regs and GCP processes.

Responsabilidades

• Build and lead CAR-T/cellular therapy unit and strategy.
• Serve as Principal Investigator on industry trials, Ph I-III.
• Set feasibility and sponsor development in portfolio planning.
• Ensure protocol conduct, subject safety and regulatory compliance.
• Oversee safety management for CRS/neurotoxicity and patient care.
• Represent unit at sponsor meetings, site visits, audits; mentor team.

Conhecimentos

CAR-T Cell Therapy

Hematology-Oncology Board Cert

Clinical Trial Leadership

FDA/ICH GCP Knowledge

Formação académica

MD or DO with California license

Board certification in Hematology-Oncology/Medical Oncology

Descrição da oferta de emprego

Medical Director, CAR-T & Cellular Therapy

We're working with an exceptional clinical research company in Los Angeles that wants to build a CAR-T and cellular therapy unit around the right physician.

They're looking for a true CAR-T cell expert, ideally with bone marrow transplant experience, who knows what it takes to run cell therapy trials safely and well. Local connections are a bonus but not essential, and relocation candidates are very welcome.

The backing is already in place. The company is a fast growing early phase oncology network with a large patient base across Southern California, and it already competes with the major academic centres for advanced trials. Sponsor relationships, regulatory infrastructure, coordinator recruitment and training, contracts, budgets and start-up are all handled by an experienced central team. You focus on the science and the patients.

The role

• Build and lead the company's CAR-T and cellular therapy unit
• Serve as Principal Investigator on industry sponsored cell therapy and hematologic malignancy trials, Phase I to III
• Work with company leadership on feasibility, portfolio strategy and sponsor development
• Take responsibility for protocol conduct, subject safety, and compliance with FDA regulations and ICH GCP
• Oversee cell therapy specific safety management, including CRS and neurotoxicity, alongside eligibility and the medical management of study participants
• Represent the unit with sponsors and CROs at investigator meetings, site visits and audits
• Mentor sub investigators, advanced practice providers and coordinators as the team grows

Who we're looking for

• MD or DO with an active, unrestricted California licence, or eligibility to obtain one
• Board certified in hematology-oncology or medical oncology
• Hands on experience with CAR-T or other cellular therapy trials, as Principal Investigator or Sub Investigator
• Bone marrow or stem cell transplant experience preferred but not required
• Strong working knowledge of GCP, FDA regulations and IRB processes
• Ambitious about building something rather than maintaining it

What's on offer

• Highly competitive compensation package
• Relocation support for the right candidate
• Full benefits, malpractice cover and CME allowance
• A leadership role with direct access to senior physician leadership
• A unit designed around your clinical and scientific interests
• Full operational, regulatory and start-up support from an experienced central team
• Real ownership of the unit's scientific direction